drugset / Trial / NCT04262336

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

NCT04262336

Phase 1 Completed 22 enrolled Decibel Therapeutics
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.

Timeline

Start
2020-02-21
Primary completion
2022-07-30
Completion
2023-05-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sodium Thiosulfate Diagnostic / imaging agent 12 % Other
Comparator Sodium Thiosulfate Diagnostic / imaging agent 25 % Other